 Cystic Fibrosis Transmembrane Conductance Regulator
"Cystic Fibrosis Transmembrane Conductance Regulator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
| Descriptor ID |
D019005
|
| MeSH Number(s) |
D12.776.157.530.100.304.500 D12.776.157.530.400.175.125 D12.776.157.530.450.074.500.500.500.500 D12.776.543.550.450.175.125 D12.776.543.585.100.304.500 D12.776.543.585.400.175.125 D12.776.543.585.450.074.500.500.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis Transmembrane Conductance Regulator".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis Transmembrane Conductance Regulator".
This graph shows the total number of publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in this website by year, and whether "Cystic Fibrosis Transmembrane Conductance Regulator" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 4 | 1 | 5 | | 2003 | 1 | 2 | 3 | | 2004 | 5 | 3 | 8 | | 2005 | 1 | 1 | 2 | | 2006 | 4 | 3 | 7 | | 2007 | 5 | 3 | 8 | | 2008 | 3 | 3 | 6 | | 2009 | 7 | 2 | 9 | | 2010 | 3 | 1 | 4 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 1 | 3 | | 2013 | 4 | 0 | 4 | | 2014 | 4 | 2 | 6 | | 2015 | 6 | 1 | 7 | | 2016 | 4 | 6 | 10 | | 2017 | 4 | 4 | 8 | | 2018 | 9 | 2 | 11 | | 2019 | 7 | 9 | 16 | | 2020 | 10 | 6 | 16 | | 2021 | 12 | 10 | 22 | | 2022 | 10 | 15 | 25 | | 2023 | 1 | 22 | 23 | | 2024 | 8 | 3 | 11 | | 2025 | 3 | 4 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Profiles.
-
Gross JE, Jones MC, Buige A, Prevots DR, Kasperbauer S. Pulmonary nontuberculous mycobacterial infections among women with cystic fibrosis and non-cystic fibrosis bronchiectasis. Ther Adv Respir Dis. 2025 Jan-Dec; 19:17534666251323181.
-
Fireizen Y, Ahmed M, Vigers T, Akong K, Ryu J, Hahn A, Fanous H, Koumbourlis A, Tirakitsoontorn P, Arrieta A, Burgener EB, Koff J, Cogen JD, Bouzek DC, Hanley E, Keck A, Stout D, Bradley J, Sagel SD. Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis. Pediatr Pulmonol. 2025 Mar; 60(3):e71019.
-
Wisniewski BL, Shrestha M, Bojja D, Shrestha CL, Lee CS, Ozuna H, Rayner RE, Bai S, Cormet-Boyaka E, Reynolds SD, Kopp BT. Secondhand vape exposure regulation of CFTR and immune function in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2025 Mar 01; 328(3):L324-L333.
-
Nick HJ, Christeson SE, Bratcher PE. VX-770, Cact-A1, and Increased Intracellular cAMP Have Distinct Acute Impacts upon CFTR Activity. Int J Mol Sci. 2025 Jan 08; 26(2).
-
Zemanick ET, Ramsey B, Sands D, McKone EF, Fajac I, Taylor-Cousar JL, Mall MA, Konstan MW, Nair N, Zhu J, Arteaga-Solis E, Van Goor F, McGarry L, Prieto-Centurion V, Sosnay PR, Bozic C, Waltz D, Mayer-Hamblett N. Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment. J Cyst Fibros. 2025 Mar; 24(2):246-254.
-
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025 Mar; 13(3):256-271.
-
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med. 2025 Mar; 13(3):244-255.
-
Nick HJ, Christeson SE, Bratcher PE. The Functional Impact of VX-770 on the Cystic Fibrosis Transmembrane Conductance Regulator Is Enduring and Increases the Constitutive Activity of This Channel in Primary Airway Epithelia Generated from Healthy Donors. Biomolecules. 2024 Oct 29; 14(11).
-
Jain R, Peng G, Lee M, Keller A, Cosmich S, Reddy S, West NE, Kazmerski TM, Goralski JL, Flume PA, Roe AH, Hadjiliadis D, Uluer A, Mody S, Ladores S, Taylor-Cousar JL. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy. Chest. 2025 Feb; 167(2):348-361.
-
Costa E, Girotti S, Mathieu C, Castellani C, Ross JS, Taylor-Cousar JL, Leufkens HGM. Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union. J Cyst Fibros. 2025 Jan; 24(1):125-132.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|